ArticleDrug design, development and therapy2025
Bibliometric and Visualization Analysis of DprE1 Inhibitors to Combat Tuberculosis.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculosis (TB) poses a serious threat to public health, particularly owing to the increase in multidrug-resistant tuberculosis (MDR-TB) and extremely drug-resistant tuberculosis (XDR-TB); thus, there is an imperative need for novel treatments to tackle this issue. Decaprenylphosphoryl- Methods: Relevant studies were sourced from the Web of Science Core Collection database. VOSviewer, CiteSpace, and bibliometrics (http://bibliometric.com/) were used to construct networks based on an analysis of journals, countries, funding, institutions, authors, references, and keywords. Results: A total of 184 publications were retrieved; the total citations were 3405 times and the mean citation was 17.28 per article. The annual number of publications on DprE1 in TB has shown a significantly increasing trend. The European Journal of Medicinal Chemistry is the most published journal, with 19 articles. Lu Yu and Bin Wang contributed the most prolific authors with 18 articles. Stratified by the number of publications, India was the most prolific country that cooperated closely with the USA, UK, Japan, and United Arab Emirates. Burstness analysis of references and keywords showed that the developing research trends in this field mainly woven around "Mtb", "DprE1" and "inhibitors" during the past years. Conclusion: A systematic bibliometric study indicates that DprE1 remains a focal point in the anti-TB domain. These results can serve as a data-driven reference for future research and offer precise insights into the development of anti-TB agents associated with DprE1. To the best of our knowledge, this study is the first to comprehensively investigate DprE1 in TB by means of bibliometric analysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.